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Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) is a ligand-activated transcription factor with essential functions in the
regulation of lipid catabolism, glucose homeostasis, and inﬂammation, which makes it a potentially relevant drug target for the
treatment of major human diseases. In addition, there is strong evidence that PPARβ/δ modulates oncogenic signaling pathways
and tumor growth. Consistent with these observations, numerous reports have clearly documented a role for PPARβ/δ in cell
cycle control, diﬀerentiation, and apoptosis. However, the precise role of PPARβ/δ in tumorigenesis and cell proliferation remains
controversial. This review summarizes our current knowledge and proposes a model corroborating the discrepant data in this area
of research.
Copyright © 2008 Rolf M¨ uller et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ)
is a transcription factor that is activated by endogenous
fatty acid ligands and by synthetic agonists [1, 2]. Major
functions of PPARβ/δ are associated with the regulation of
glucose, energy, and lipid metabolism [3], and the control
of inﬂammatory responses [4, 5]. PPARβ/δ, therefore,
represents a promising drug target for the treatment of
common diseases such as obesity, metabolic syndrome,
chronic inﬂammation, and arteriosclerosis, which has led
to the development of synthetic drug agonists with sub-
type selectivity and high-aﬃnity binding [6]. Mice lacking
PPARβ/δ show an aberrant development of the placenta and
exhibit a defect in wound healing associated with alterations
in cell proliferation, diﬀerentiation, and cellular survival [7–
10]. Experimental evidence obtained with cultured cells has
provided additional strong evidence for a role of PPARβ/δ
in cell cycle regulation and diﬀerentiation in diﬀerent cell
types (see Table 1). Consistent with these physiological
functions, there is also clear evidence for a role of PPARβ/δ
in oncogenesis and tumor growth. These ﬁndings might
provide a basis for the development of novel strategies for
thetreatmentofproliferativediseases,butalsodemandsome
caution with respect to the clinical use of PPARβ/δ-directed
dugs. A detailed knowledge of the role of PPARβ/δ in cell
proliferation and its eﬀects on tumor growth are therefore of
paramount importance.
2. PPARβ/δ AFFECTS TUMORIGENESIS
T h er o l eo fP P A R β/δ in tumorigenesis has been explored
predominantly in epithelial tumors of the skin, lung, and
intestine and in the tumor stroma. PPARβ/δ inhibits chem-
ically induced skin carcinogenesis, since an enhancement
of chemically induced skin tumor growth is seen in mice
with a global disruption of Pparb [38]. However, no eﬀect
on skin carcinogenesis is observed in mice lacking PPARβ/δ
speciﬁcally in basal keratinocytes [39], suggesting that the
tumor suppressive eﬀect of PPARβ/δ is due to a function
in other cell types. A tumor suppressive role for PPARβ/δ
has also been described for a transgenic mouse model of
Raf oncogene-induced lung adenoma formation, but similar
to skin carcinogenesis the precise mechanisms and cell
types involved are not known [40]. Eﬀects of PPARβ/δ
have also been reported in diﬀerent mouse models of
intestinal carcinogenesis, that is, the Apc/Min mouse lacking
functional APC protein and chemically induced intestinal
carcinogenesis, but these studies diﬀer in their conclusions
[41]. Thus, PPARβ/δ has been reported to have either no
eﬀect on intestinal tumorigenesis [9] to attenuate tumor
growth by promoting terminal diﬀerentiation of colonocytes2 PPAR Research
Table 1: Eﬀects of PPARβ/δ on cell proliferation and diﬀerentiation.
Cell type Exp. approach
Role of PPAR β/δ in Aﬀected pathway References
Prolif. Diﬀ.
Epithelial cells
Keratinocyte Agonist, wt versus null    AKT [11]
Keratinocyte Agonist, wt versus null    ERK [12–17]
Keratinocyte Agonist, RNAi, wt versus
null
  [18, 19]
Adipocyte Agonist, wt versus null   PPARγ [20–22]
Trophoblast wt versus null   AKT [10, 23]
Paneth cells (in vivo) wt versus null   Hedgehog [24]
Hepatic stellate cell Agonist   [25]
Oligodendrocyte Agonist   [26]
Mesenchymal cells
Fibroblast Agonist   ( ∗) G0S2∗∗,P T E N [27]
Fibroblast wt versus null,
re-expression in null
  p57KIP2 [28, 29]
Vascular smooth muscle
cells Agonist   PDGF [30]
Tumor endothelium wt versus null    [29]
Endothelial cells Agonist    [31]
Human tumor cell lines
MCF-7 breast carcinoma;
UACC903 melanoma Agonist   [32]
HT29, HCT116, LS-174T
colon carcinoma; HepG2,
HuH7 hepatoma
Agonist   [33]
HCT116 colon carcinoma RNAi   [34]
SH-SY5Y neuroblastoma Agonist   [35]
NSC lung carcinoma Agonist   AKT, NFκB[ 36]
A549 NSC lung ca. Agonist   [37]
∗ transdiﬀerentiation into myoﬁbroblasts.
∗∗G0S2: G0/G1 switch gene 2 (cell cycle inhibitor).
[33, 42–45] or to potentiate tumorigenesis [46–48]. The
reason for these discrepancies remains unclear at present
[49], but may be in part related to a function of PPARβ/δ
in host cells recruited by the tumor, such as endothelial
cells, ﬁbroblasts, and macrophages [50]. Indeed, recent work
showed that PPARβ/δ is indispensable for the formation
of functional tumor microvessels [29, 51], suggesting that
PPARβ/δ may have diﬀerent functions in the tumor stroma
and in tumor cells with opposing eﬀects on tumor growth.
T h er o l eo fP P A R β/δ in tumor stroma cells is further
discussed below.
3. ATTENUATION OF TUMOR STROMA CELL
PROLIFERATION BY PPARβ/δ
The inhibition of syngeneic tumor growth in mice lacking
PPARβ/δ strongly correlates with a lower density of func-
tional tumor microvessels [29, 51], which is associated with
a striking increase in the proliferation of tumor endothelial
cells and an inhibition of their maturation [29]. The imma-
ture microvascular structures are also frequently surrounded
by perivascular cells expressing vast amounts of α-smooth
muscle actin, giving rise to an overall picture characteristic
oftumorendothelialhyperplasia.Invivomicroarrayanalysis
led to the identiﬁcation of PPARβ/δ target genes with
known inhibitory functions in angiogenesis, including Cd36
and Cdkn1c [29]. A crucial function of CD36 is to serve
as a receptor for thrombospondins which are known to
attenuate the proliferation of endothelial cells [52], and
Cdkn1c codes for the cyclin-dependent kinase inhibitor
p57KIP2 [53]. Consistent with the existence of a PPARβ/δ −
p57KIP2 pathway in stroma cell types, it was shown that the
forcedexpressionofPPARβ/δ inPparbnullﬁbroblastsresults
in a Cdkn1c-dependend inhibition of cell proliferation [29].
Other PPARβ/δ target genes with potential functions in cell
proliferation and diﬀerentiation were identiﬁed in the same
study, suggesting that PPARβ/δ regulates multiple genes with
functions in cell proliferation in the context of tumor stroma
development and tumor angiogenesis.Rolf M¨ uller et al. 3
An antiproliferative eﬀect of PPARβ/δ agonists in ﬁbrob-
lastsandvascularsmoothmusclecellshasalsobeenobserved
intwootherstudies[27,30],whileoppositeeﬀectshavebeen
described for endothelial cells [31]. At present, it is diﬃcult
to explain these apparent discrepancies, since they cannot be
narrowed down to a single parameter, such as experimental
strategy, cell type, expression level of PPARβ/δ, or state of
the cell (e.g., metabolic activity, proliferative status, stage of
diﬀerentiation, exogenous factors). This issue is discussed
further in the Conclusions section below.
4. ROLE OF PPARβ/δ IN WOUND HEALING AND
KERATINOCYTE PROLIFERATION
Pparb null mice exhibit a defect in wound healing by
inhibiting apoptosis in keratinocytes [8]. This survival
function of PPARβ/δ has been explained by an induction of
AKT/protein kinase B (PKB) activity by PPARβ/δ resulting
from an upregulation of the Pdk1 and Ilk genes and a
downregulation of Pten [11]. Increased AKT signaling is
generally associated with enhanced proliferation, yet others
havereportedthatPPARβ/δ inhibitscellproliferation[7,15].
In this case, however, AKT activity was not aﬀected by
PPARβ/δ activation. Instead, a downregulation of protein
kinase C and MAP kinase signaling was observed [14].
The reason for these discrepancies is not clear at present,
however, in light of the relatively small eﬀects of PPARβ/δ
on the signaling pathways discussed above it is possible that
subtlediﬀerencesintheexperimentalsettingsaccountforthe
apparent lack of consistency.
5. ROLE OF PPARβ/δ IN DIFFERENTIATION
Mice lacking PPARβ/δ show a very high degree of embryonic
lethality due to an aberrant development and malfunction
of the placenta [7, 9, 10]. Consistent with this ﬁnding,
the diﬀerentiation and metabolic functions of trophoblast
giant cells in vitro are dependent on PPARβ/δ [10]. In
the same model, stimulatory eﬀect of PPARβ/δ on AKT
signaling was observed. Another tissue where PPARβ/δ plays
ar o l ei nd i ﬀerentiation is the digestive tract, where PPARβ/δ
promotes the diﬀerentiation of Paneth cells in the intestinal
crypts by down-regulating the hedgehog signaling pathway
[24]. A diﬀerentiation promoting eﬀect of PPARβ/δ has
alsobeendescribedforkeratinocytes,adipocytes,endothelial
cells, and oligodendrocytes (see Table 1 for details).
6. CONCLUSIONS
Studies addressing the role of PPARβ/δ in diﬀerentiation
have yielded a consistent picture and point to a diﬀerenti-
ation promoting in a wide spectrum of diﬀerent cell types.
Numerous reports have also clearly documented a role for
PPARβ/δ incellproliferationandtumorigenesis,yetdiﬀerent
studies have produced controversial results, even though
the majority of studies describe antiproliferative eﬀects by
PPARβ/δ (see Table 1).
One reason for the apparently discrepant data may be
associated with the use of diﬀerent experimental strategies.
Since the precise mechanisms of PPARβ/δ-mediated gene
regulation are often not known, the results from gain-
of-function and loss-of-function are not always easy to
interpret. Thus, ligand activation and genetic inactivation
of PPARβ/δ may have opposite eﬀects, as in the case of
classical PPRE-driven genes, but may also give similar results
in other regulatory settings. The latter has been described,
for instance, for PPARβ/δ-mediated gene repression through
direct interaction with the transcriptional repressor BCL-6
in macrophages [54]. This aspect has not been thoroughly
analyzed to date so that it is diﬃcult to judge its contribution
to the deviant results published in diﬀerent studies.
To help explain the discrepant published data, we would
therefore like to put forward another hypothesis. This model
postulates that PPARβ/δ is not a bona ﬁde cell cycle regulator
with a deﬁned function but rather aﬀects the expression
of both inducers and inhibitors of cell proliferation (e.g.,
regulatorsoftheAKTpathwayandPDGFversusthecellcycle
inhibitors p57KIP2 and G0S2;s e eTable 1). This is conceivable
both in view of the large number of potential PPAR target
genes, estimated at several thousand for the human genome
[55]. Depending on the particular cell type, the metabolic
or proliferative state of the cell or other experimental
conditions, positive or negative regulators of the cell cycle
may prevail resulting in opposite eﬀects. This suggests that
the precise eﬀects of PPARβ/δ on cell proliferation are
highly context-dependent and not predictable on the basis
of our current knowledge. Clearly, a better and detailed
understanding of the eﬀects of PPARβ/δ on cell cycle
regulation and diﬀerentiation will be a prerequisite for the
development of PPARβ/δ directed drugs and their clinical
application.
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